Original language | English |
---|---|
Pages (from-to) | e100 |
Journal | The Lancet Oncology |
Volume | 23 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2022 |
Externally published | Yes |
6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting
Naysha Becerra-Chauca, Wendy Nieto-Gutierrez, Alvaro Taype-Rondan
Research output: Contribution to journal › Letter › peer-review
4
Scopus
citations